Neoleukin Therapeutics Stock Total Asset
Neoleukin Therapeutics fundamentals help investors to digest information that contributes to Neoleukin Therapeutics' financial success or failures. It also enables traders to predict the movement of Neoleukin Stock. The fundamental analysis module provides a way to measure Neoleukin Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neoleukin Therapeutics stock.
Neoleukin |
Neoleukin Therapeutics Company Total Asset Analysis
Neoleukin Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Neoleukin Therapeutics Total Asset | 115.95 M |
Most of Neoleukin Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neoleukin Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, Neoleukin Therapeutics has a Total Asset of 115.95 M. This is 98.46% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is 99.61% higher than that of the company.
Neoleukin Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neoleukin Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neoleukin Therapeutics could also be used in its relative valuation, which is a method of valuing Neoleukin Therapeutics by comparing valuation metrics of similar companies.Neoleukin Therapeutics is currently under evaluation in total asset category among its peers.
Neoleukin Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | (35.02 M) | |||
| Shares Outstanding | 2.35 M | |||
| Shares Owned By Insiders | 16.46 % | |||
| Shares Owned By Institutions | 45.58 % | |||
| Number Of Shares Shorted | 26.4 K | |||
| Price To Earning | (4.60) X | |||
| Price To Book | 0.44 X | |||
| EBITDA | (56.48 M) | |||
| Net Income | (57.56 M) | |||
| Cash And Equivalents | 116.46 M | |||
| Cash Per Share | 2.73 X | |||
| Total Debt | 12.07 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 12.78 X | |||
| Book Value Per Share | 34.18 X | |||
| Cash Flow From Operations | (45.61 M) | |||
| Short Ratio | 1.70 X | |||
| Earnings Per Share | (12.28) X | |||
| Price To Earnings To Growth | (0.03) X | |||
| Target Price | 1.5 | |||
| Beta | 1.1 | |||
| Market Capitalization | 8.2 M | |||
| Total Asset | 115.95 M | |||
| Retained Earnings | (451.06 M) | |||
| Working Capital | 88.07 M | |||
| Current Asset | 289 K | |||
| Current Liabilities | 1.02 M | |||
| Z Score | -5.73 | |||
| Net Asset | 115.95 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |